Solid Biosciences Inc. (SLDB) Stock Score, Valuation & Financial Research

Solid Biosciences Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SLDB

Solid Biosciences Inc. does not currently have a complete Wall Street Score. The stored market price is USD 7.13. These figures are a research snapshot, not a buy or sell recommendation.

What Solid Biosciences Inc. does

Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Solid Biosciences is a life sciences company focused on developing gene transfer therapies for neuromuscular and cardiac diseases. The company operates as a clinical-stage biotechnology firm that has not yet generated revenue from product sales and relies on capital raises to fund its research and development activities.

Products and services

  • The company is developing a pipeline of gene transfer candidates, including SGT-003, SGT-212, and SGT-501, aimed at treating conditions such as Duchenne muscular dystrophy.

Customer types

Patients with neuromuscular and cardiac diseases.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its gene transfer candidates. Source

Business strengths to evaluate

  • Pipeline of novel gene transfer candidates Source

Business risks and research considerations

  • History of significant net losses and lack of product revenue Source
  • Need for additional funding to continue operations Source
  • Clinical trial delays or failures Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SLDB financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 7.13
Market capitalization:
701.45M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -207.1M
Free cash flow:
USD -157.44M
Cash:
USD 159.39M
Total debt:
USD 20.16M
EPS:
USD -1.91

What stands out

  • Free cash flow is USD -157.44M, negative for the stored period.
  • The balance sheet shows USD 159.39M of cash versus USD 20.16M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 139.24M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SLDB

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can SLDB fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is SLDB likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for SLDB to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of SLDB's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research SLDB

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.